N-telopeptide of type i collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastases

International Journal of Clinical Oncology

Volumn 15, Issue 5, 2010, Pages 484-488

  Kaira, Rieko ^a   Murakami, Haruyasu ^a   Kaira, Kyoichi ^a   Takahashi, Toshiaki ^a   Tsuya, Asuka ^a   Nakamura, Yukiko ^a   Naito, Tateaki ^a   Endo, Masahiro ^a   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Bone metastases; NSCLC; NTX telopeptide; Survival; Therapeutic response

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CISPLATIN; CREATININE; DOCETAXEL; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN URINE LEVEL; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COLLAGEN TYPE I; DRUG MONITORING; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEPTIDES; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78149361880     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-010-0100-7     Document Type: Article

References (14)

1. RE Coleman 1997 Skeletal complications of malignancy Cancer (Phila) 80 1588 1594 1:STN:280:DyaK1c%2Fis1Onuw%3D%3D 10.1002/(SICI)1097-0142(19971015)80: 8+<1588::AID-CNCR9>3.0.CO;2-G
2. DJ Bloomfield 1998 Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancer? An evidence-based review J Clin Oncol 16 1218 1225 1:CAS:528:DyaK1cXitVKitbs%3D 9508210
3. L Costa LM Demers A Gouveia-Oliveria, et al. 2002 Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status J Clin Oncol 20 850 856 1:CAS:528:DC%2BD38XhsVGmtLo%3D 10.1200/JCO.20.3.850 11821470 (Pubitemid 34111395)
4. A Lipton L Costa SM Ali, et al. 2001 Bone markers in the management of metastatic bone disease Cancer Treat Rev 27 181 185 1:CAS:528: DC%2BD3MXktlCktb8%3D 10.1053/ctrv.2000.0212 11417969 (Pubitemid 32452019)
5. LM Demers L Costa A Lipton 2000 Biochemical markers and skeletal metastases Cancer (Phila) 88 2919 2926 1:CAS:528:DC%2BD3cXksVCmsL4%3D 10.1002/1097-0142(20000615)88:12+<2919::AID-CNCR7>3.0.CO;2-Z
6. JE Brown RJ Cook P Major, et al. 2005 Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors J Natl Cancer Inst 97 59 69 1:CAS:528:DC%2BD2MXisVarsA%3D%3D 10.1093/jnci/dji002 15632381
7. H Namazi 2008 Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity J Thorac Oncol 3 228 236 10.1097/JTO.0b013e318180721d
8. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437 (Pubitemid 30099779)
9. A Lipton RJ Cook P Major, et al. 2007 Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity Oncologist 12 1035 1043 1:CAS:528:DC%2BD2sXht1Krs73O 10.1634/theoncologist.12-9-1035 17914073 (Pubitemid 350007015)
10. A Lipton R Cook F Saad, et al. 2008 Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid Cancer (Phila) 113 193 201 1:CAS:528:DC%2BD1cXos1yht7Y%3D 10.1002/cncr.23529 (Pubitemid 351976401)
11. H Nakamura K Kashiwabara H Yagyu, et al. 1998 Assisted diagnosis of lung cancer metastases to the bone using a bone absorption marker Jpn J Lung Cancer 38 123 130
12. DR Eyre 1991 New biomarkers of bone resorption J Clin Endocrinol Metab 74 470A 470C
13. DA Hansen MA Weis AM Bollen, et al. 1992 A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine J Bone Miner Res 7 1251 1258 10.1002/jbmr.5650071119
14. M Izumi Y Nakanishi K Takayama, et al. 2001 Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma Cancer (Phila) 91 1487 1493 1:STN:280:DC%2BD3M3mtFCrsw%3D%3D 10.1002/1097-0142(20010415)91:8<1487::AID-CNCR1156>3.0.CO;2-2 (Pubitemid 32319259)